trial

Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients

NCTId NCT00534898
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Withdrawn
Enrollment —
Sponsored by Beersheva Mental Health Center
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Withdrawn
Enrollment
—
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
—
Primary completion
—
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
bexaroteneFenretinide

Sponsors

Beersheva Mental Health CenterLead Sponsor

Investigators

2
Prof. Vladimir Lerner, MD, PhDPrincipal Investigator
Chanoch Miodownik, MDStudy Director

Sites

1 total
Be'er Sheva, Hadera, Israel

Facts & assertions

2 sourced
Phase
PHASE3
Status
WITHDRAWN
relationships
The graph out of here
drug
bexarotene
drug
Fenretinide
drug
lead_sponsor
Beersheva Mental Health Center
company
indication
Schizoaffective Disorder
indication
Cognition
indication
Psychotic Disorders
indication
investigator
Prof. Vladimir Lerner, MD, PhD
person
Chanoch Miodownik, MD
person